Navigation Links
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Date:11/16/2011

ent and Chief Executive Officer of Sonus Pharmaceuticals Inc., a publicly traded cancer therapeutics company.  During his tenure, he refocused the company on oncology drug development, and oversaw development of the company's lead cancer therapeutic through a pivotal Phase 3 trial conducted under a special protocol assessment.  In addition, he played an integral role in establishing and managing collaborations with partners, raising capital from public markets and ultimately completing a reverse merger with Oncogenex Pharmaceuticals Inc.  

In 2009, Martino joined with the cofounders of Arzeda Corp., a privately held company focused on enzyme design and development using technology licensed from the University of Washington.  During his tenure as the company's first CEO, he oversaw the company's start-up and fundraising activities, both through private investment and collaborations. In 2010, Martino joined CareFusion Corporation and held multiple positions including Senior Vice President and General Manager of diagnostics and Senior Vice President of Innovation, Business Development and Strategy.  Earlier in his career, he held multiple positions during a 17-year tenure at Mallinckrodt in strategic planning, business development, marketing, and general management, where he completed multiple acquisitions and licensing agreements and led a major restructuring of the company.

Martino received an M.B.A. from Virginia Tech and a bachelor's degree from Roanoke College. He currently serves on the Board of Directors of Arzeda Corp.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as mono-therapy treatment for adult and elderly patients with r
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Announces Transition in Company Leadership
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Neurocrine Biosciences Reports Third Quarter 2011 Results
6. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
7. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
8. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
9. Amarillo Biosciences Issues Corporate Update
10. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 ­ RedBrick Health , a ... technology, today announces that EmblemHealth , the ... company, is now providing the RedBrick Compass health assessment, ... to all of its members. EmblemHealth is among the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), ... and distributor of probiotics products in China, today announced ... ended December 31, 2010. Preliminary unaudited fiscal ... and $33 million compared with $23 million for the ...
... Therapeutics (NYSE Amex: CXM ) reported that ... 2010 has been accepted by the NYSE Amex LLC. ... As previously reported, a communication from the staff of ... was considered to be noncompliant with one of the ...
... 21, 2011 Leading organizations understand the value of ... operational tactics across numerous functions. As pharmaceutical, biotechnology and ... must also evolve and develop new capabilities while refining ... " The Future of Market Research: Challenges ...
Cached Biology Technology:China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue 2China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue 3Cardium's Exchange Listing Compliance Plan Accepted by NYSE Amex 2Cardium's Exchange Listing Compliance Plan Accepted by NYSE Amex 3Cardium's Exchange Listing Compliance Plan Accepted by NYSE Amex 4Role of Market Research Evolving to Take on a More Strategic Responsibility 2
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... 2009, 1,547 ART children were born in public clinics in Denmark, ... in 25 and 50 years respectively. The authors of the study ... policy would lead to cost savings of 67 - 111 million ... IVF cohort are 50 years of age, the government would have ...
... PHOENIX, Ariz. July 6, 2011 A first-of-its-kind study of ... today by TGen and the Virginia G. Piper Cancer Center at ... 3-7 in Amsterdam. Researchers for the first time sequenced the ... the lung, said Dr. Glen Weiss, the first author of the ...
... America,s tallest bird, the statuesque whooping crane ( Grus americana ... at the Smithsonian,s National Zoological Park. An 11-year-old male whooping ... and is now on exhibit in the nation,s capital. Whooping ... the United States. There are only eight other zoos in ...
Cached Biology News:The long-term fiscal impact of funding cuts for IVF in Denmark 2First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference 2National Zoo Welcomes Whooping Crane 2
Request Info...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... culture chambered coverslips are convenient ... staining and imaging. The chambered ... with standard optical-quality coverslips and ... to use. Preassembled CultureWell systems ...
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
Biology Products: